Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
评价吸入用XQ-001在健康受试者中单次及多次给药的安全性、耐受性和药代动力学的随机、双盲、安慰剂对照的Ⅰa期临床研究
[Translation] A randomized, double-blind, placebo-controlled Phase Ia clinical study to evaluate the safety, tolerability and pharmacokinetics of single and multiple doses of XQ-001 for inhalation in healthy subjects
主要研究目的:
评价吸入用XQ-001在中国健康成年受试者中单次和多次雾化吸入给药后的安全性和耐受性。
次要研究目的:
评估吸入用XQ-001单次和多次雾化吸入给药后的药代动力学(PK)特征。
[Translation] Primary study objective:
To evaluate the safety and tolerability of XQ-001 for inhalation after single and multiple nebulized inhalation administration in healthy Chinese adult subjects.
Secondary study objective:
To evaluate the pharmacokinetic (PK) characteristics of XQ-001 for inhalation after single and multiple nebulized inhalation administration.
100 Clinical Results associated with Chengdu Beite Xinqi Biomedical Co., Ltd.
0 Patents (Medical) associated with Chengdu Beite Xinqi Biomedical Co., Ltd.
100 Deals associated with Chengdu Beite Xinqi Biomedical Co., Ltd.
100 Translational Medicine associated with Chengdu Beite Xinqi Biomedical Co., Ltd.